Looking to expand your partner network with the latest in the field of Macular degeneration? Consider joining Inpart's global network for free.
News and Trends 1 Dec 2022
FDA clears SparingVision’s investigational new drug application to treat ocular diseases
SparingVision today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) for SPVN06. The genomic medicine company has had its developing vision-saving treatments for ocular diseases, lead gene independent therapy for the treatment of retinitis pigmentosa (RP), a form of rod-cone dystrophy (RCD) and the most prevalent […]